QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

23,600 signal articles · 320 in last 24h · 112,439 total before filter · latest 34m ago
320last 24h
2139last 7d
381● bullish (7d)
186● bearish (7d)
204publishers
AllMacro299Earnings1210M&A91Regulatory22Product13Analyst20
✕ clear all filtersticker: PFEsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
Bloomberg21d agoneutral
Trump Takes Another Swing at Drug Industry in Made-in-USA Push

(Bloomberg) -- President Donald Trump’s threat of 100% tariffs against generic medicines is a major expansion of a strategy he’s been using against the pharmaceutical industry since his second term began. Most Read from BloombergTrump’s 100% Generic Drug Duty Threatens US Low-Cost SupplyApple to Launch ‘Upgrade’ Device Leasing Program With Klarna to Spur SalesTrump Extends Pardons to Companies, Echoing a 17th Century KingSpaceX Set to Unlock $116 Billion in Shares After IPO Restrictions LiftKrem

PFE
JPMorgan resets LLY stock target on drug demand
TheStreet35d agoneutral
JPMorgan resets LLY stock target on drug demand

Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well. On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc. (PFE), Eli Lilly, and Teva Pharmaceutical Industries Ltd. ...

LLYPFE
Manhattan High-Rise at Risk of Collapse, Prompting Evacuations
The Wall Street Journal36d agoneutral
Manhattan High-Rise at Risk of Collapse, Prompting Evacuations

A high-rise building in Manhattan was at risk of collapse after columns buckled and floors sagged, officials said Tuesday, prompting an emergency response during the rush-hour commute. Fire officials said they received a report that bricks were falling from the 38-story building, in the city’s midtown district just before 8 a.m. Officials determined that two columns had buckled on the building’s 21st and 22nd floors and that several floors near the columns were sagging. No injuries were reported, fire officials said.

PFE
Bloomberg41d agoneutral
Trump Financial Disclosure Shows 21,000 Trades in 2025

(Bloomberg) -- President Donald Trump made more than 21,000 securities trades in his first year back in office, often in intense bursts tied to market events he created.Most Read from BloombergExxon to Change Name for First Time in Decades After RedomicileMeta Is Planning a Cloud Business to Sell AI Computing PowerGermany Rejects Trump’s Demands for NATO Loyalty to WashingtonRussia Indicates Ukraine Fired Long-Range Ballistic MissileKrafton Agrees to Pay ‘Subnautica 2’ Bonuses as Developer’s CEO

AAPLAVGOLMTMCDMSFTPFETSLA
Bloomberg48d agoneutral
Nike Joins Alphabet, Walmart in Hiring a CFO From the Outside

(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a

CVSGOOGGOOGLLLYLOWNKEPFEPYPL+2
Big pharma taps UK playbook to pressure Europe on drug prices
Reuters Videos56d agoneutralVIDEO
Big pharma taps UK playbook to pressure Europe on drug prices

<body><p>STORY: Big pharma is receiving pushback from European capitals on drug pricing.&nbsp;</p><p>So they’re turning to a playbook that brought them success in the UK.</p><p>Making threats to pull investment plans to pressure policymakers.&nbsp;</p><p>The industry notched a win when the British government agreed to increase medicine spending as part of a broader deal to avoid U.S.-imposed tariffs.&nbsp;</p><p>The latest nation to face pressure is Germany, which has been debating legislation to tighten spending on medicines.&nbsp;</p><p>A Reuters European Pharma correspondent Maggie Fick said pressure in the last week has ramped up.&nbsp;</p><p>"The CEO of Pfizer wrote a letter to the German chancellor warning that their future investments in the country may be at risk over these proposed changes to pricing laws."</p><p>Meanwhile, AstraZeneca warned that it may not launch new medicines in Germany if these changes go ahead.</p><p>Earlier in June, Eli Lilly announced it would halve a planned $2.7 billion investment, also citing the proposed legislation.&nbsp;</p><p>This bid to cap costs has centered Germany in a broader tussle between drugmakers and European governments that began several months ago.</p><p>That tension has been sharpened by the impact on Europe of U.S. President Donald Trump's pricing push.</p><p>This aims to tie prescription medicine prices in the lucrative U.S. market to ​lower prices elsewhere, including in Europe.</p><p>Major drugmakers have struck deals with the White House to lower drug costs in exchange for tariff exemptions, adding to pressure for increasing prices elsewhere.</p></body>

LLYPFE
This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It’s a Flawless Safe-Haven for Retirees
24/7 Wall St.62d agoneutral
This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It’s a Flawless Safe-Haven for Retirees

Pfizer (NYSE:PFE) is in the middle of its biggest reinvention in a generation, leaning on the Seagen oncology platform and the freshly closed Metsera obesity assets to offset a COVID revenue cliff and looming patent losses. With shares at $25.60 and yielding nearly 7%, the only question that matters for income investors is whether that ... This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It’s a Flawless Safe-Haven for Retirees

PFE
Investing.com73d agoneutral
Could GLP-1 drugs become oncology’s next big opportunity?

Investing.com -- GLP-1 weight-loss and diabetes drugs may have a future role in cancer prevention and treatment, according to new research highlighted by Citi ahead of the 2026 American Society of Clinical Oncology (ASCO) meeting, adding another potential growth avenue to an already booming drug class.

CLLYPFE
Scott Melker explains why the Fed was secretly designed for banks
Yahoo Finance Video82d agoneutralVIDEO
Scott Melker explains why the Fed was secretly designed for banks

Scott Melker discusses the history and structure of the Federal Reserve and presents bitcoin as a decentralized alternative. “The Daily Wolf with Scott Melker” airs on Yahoo Finance every day at 12:00 p.m. Tune in for your daily dose of all things crypto.Make sure to also check out Yahoo Finance's new crypto hub to find the latest crypto-related news.

PFE
Value Stocks With Earnings Strength Post 3,500% Run Since 2000
Bloomberg84d agoneutral
Value Stocks With Earnings Strength Post 3,500% Run Since 2000

(Bloomberg) -- Turns out, loading up on technology giants isn’t the only route to better returns. Value companies, too, stand a decent chance of trouncing the market — as long as several conditions are met. Most Read from BloombergUS Lawmakers Plan New $130 Fee for Electric Vehicle OwnersNATO Is Starting to Consider Hormuz Mission to Protect ShipsHasbro Cancels Dungeons & Dragons Game From ‘Star Wars’ VeteranUS 30-Year Yield Hits Highest Since 2007 as Selloff DeepensTrump Threatens Iran With ‘Bi

GSPFEWMT
Valneva Q1 Earnings Call Highlights
MarketBeat91d agoneutral
Valneva Q1 Earnings Call Highlights

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

PFE
Transcript: Valneva Q1 2026 Earnings Conference Call
Benzinga91d agoneutral
Transcript: Valneva Q1 2026 Earnings Conference Call

On Wednesday, Valneva (NASDAQ:VALN) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://edge.media-server.com/mmc/p/xbkzgkz7 Summary Valneva SE reported first-quarter revenues of approximately €30 million, with a decline from the previous

PFE